172 related articles for article (PubMed ID: 34599023)
1. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599023
[TBL] [Abstract][Full Text] [Related]
2. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract][Full Text] [Related]
4. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38105142
[TBL] [Abstract][Full Text] [Related]
5. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
Msaouel P; Goswami S; Thall PF; Wang X; Yuan Y; Jonasch E; Gao J; Campbell MT; Shah AY; Corn PG; Tam AL; Ahrar K; Rao P; Sircar K; Cohen L; Basu S; Duan F; Jindal S; Zhang Y; Chen H; Yadav SS; Shazer R; Der-Torossian H; Allison JP; Sharma P; Tannir NM
Sci Transl Med; 2022 Apr; 14(641):eabm6420. PubMed ID: 35442707
[TBL] [Abstract][Full Text] [Related]
6. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB; He K; Planchard D; Reck M; Popat S; Herbst RS; Leal TA; Shazer RL; Yan X; Harrigan R; Peters S;
Ann Oncol; 2024 Jan; 35(1):66-76. PubMed ID: 37866811
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA; Msaouel P; Haymaker CL; Matin SF; Campbell MT; Zurita AJ; Shah AY; Wistuba II; Marmonti E; Duose DY; Parra ER; Soto LMS; Laberiano-Fernandez C; Lozano M; Abraham A; Hallin M; Chin CD; Olson P; Der-Torossian H; Yan X; Tannir NM; Wood CG
Nat Commun; 2023 May; 14(1):2684. PubMed ID: 37164948
[TBL] [Abstract][Full Text] [Related]
8. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Bauer T; Cho BC; Heist R; Bazhenova L; Werner T; Goel S; Kim DW; Adkins D; Carvajal RD; Alva A; Eaton K; Wang J; Liu Y; Yan X; Christensen J; Neuteboom S; Chao R; Pant S
Invest New Drugs; 2022 Oct; 40(5):990-1000. PubMed ID: 35767205
[TBL] [Abstract][Full Text] [Related]
9. Sitravatinib combined with PD-1 blockade enhances cytotoxic T-cell infiltration by M2 to M1 tumor macrophage repolarization in esophageal adenocarcinoma.
Sweeney R; Omstead AN; Fitzpatrick JT; Zheng P; Gorbunova A; Grayhack EE; Goel A; Khan AF; Kosovec JE; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
Carcinogenesis; 2024 Apr; 45(4):210-219. PubMed ID: 38019590
[TBL] [Abstract][Full Text] [Related]
10. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models.
Du W; Huang H; Sorrelle N; Brekken RA
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385724
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
Hanna GJ; Villa A; Nandi SP; Shi R; ONeill A; Liu M; Quinn CT; Treister NS; Sroussi HY; Vacharotayangul P; Goguen LA; Annino DJ; Rettig EM; Jo VY; Wong KS; Lizotte P; Paweletz CP; Uppaluri R; Haddad RI; Cohen EEW; Alexandrov LB; William WN; Lippman SM; Woo SB
JAMA Oncol; 2024 Jan; 10(1):32-41. PubMed ID: 37971722
[TBL] [Abstract][Full Text] [Related]
14. ISA101 and nivolumab for HPV-16
Sousa LG; Rajapakshe K; Rodriguez Canales J; Chin RL; Feng L; Wang Q; Barrese TZ; Massarelli E; William W; Johnson FM; Ferrarotto R; Wistuba I; Coarfa C; Lee J; Wang J; Melief CJM; Curran MA; Glisson BS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193933
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.
Dolan M; Mastri M; Tracz A; Christensen JG; Chatta G; Ebos JML
PLoS One; 2019; 14(8):e0220101. PubMed ID: 31369645
[TBL] [Abstract][Full Text] [Related]
17. A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.
Ingham M; Lee S; Van Tine BA; Choy E; Oza J; Doshi S; Ge L; Oppelt P; Cote G; Corgiat B; Sender N; Sta Ana S; Panchalingam L; Petricoin E; Schwartz GK
Clin Cancer Res; 2023 Mar; 29(6):1031-1039. PubMed ID: 36548343
[TBL] [Abstract][Full Text] [Related]
18. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S; Matei DE; Konstantinopoulos PA; Wang BX; Gadalla R; Block MS; Jewell A; Gaillard SL; McHale M; McCourt C; Temkin S; Girda E; Backes FJ; Werner TL; Duska L; Kehoe S; Colombo I; Wang L; Li X; Wildman R; Soleimani S; Lien S; Wright J; Pugh T; Ohashi PS; Brooks DG; Fleming GF
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288469
[TBL] [Abstract][Full Text] [Related]
19. [Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas].
Stuschke M; Budach V; Dinges S; Jahnke K; Budach W; Heselmann I; Unger A; Stüben G; Sack H
Strahlenther Onkol; 1994 Dec; 170(12):689-99. PubMed ID: 7817270
[TBL] [Abstract][Full Text] [Related]
20. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
